Authors: | Stone, R. M.; Mandrekar, S.; Sanford, B. L.; Geyer, S.; Bloomfield, C. D.; Dohner, K.; Thiede, C.; Marcucci, G.; Lo-Coco, F.; Klisovic, R. B.; Wei, A.; Sierra, J.; Sanz, M. A.; Brandwein, J. M.; de Witte, T.; Niederwieser, D.; Appelbaum, F. R.; Medeiros, B. C.; Tallman, M. S.; Krauter, J.; Schlenk, R. F.; Ganser, A.; Serve, H.; Ehninger, G.; Amadori, S.; Larson, R. A.; Dohner, H. |
Abstract Title: | The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): An international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]) |
Meeting Title: | 57th Annual Meeting of the American Society of Hematology (ASH) |
Journal Title: | Blood |
Volume: | 126 |
Issue: | 23 |
Meeting Dates: | 2015 Dec 5-8 |
Meeting Location: | Orlando, FL |
ISSN: | 0006-4971 |
Publisher: | American Society of Hematology |
Date Published: | 2015-12-03 |
Language: | English |
ACCESSION: | WOS:000368019000070 |
PROVIDER: | wos |
DOI: | 10.1182/blood.V126.23.6.6 |
Notes: | Meeting Abstract: 6 -- 57th Annual Meeting of the American-Society-of-Hematology -- DEC 05-08, 2015 -- Orlando, FL -- Source: Wos |